Akebia Therapeutics Inc. has announced the dosing of the first patient in a Phase 2 clinical trial evaluating praliciguat, an oral, once-daily soluble guanylate cyclase (sGC) stimulator, for the treatment of biopsy-confirmed focal segmental glomerulosclerosis $(FSGS)$, a rare kidney disease. The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 60 adults with FSGS who are already receiving maximally tolerated doses of an ACE inhibitor or angiotensin receptor blocker. The trial’s primary endpoint is the change from baseline in urine protein-to-creatinine ratio (UPCR) at Week 24. A secondary endpoint will assess the percentage of patients achieving partial remission at Week 24. All participants will receive praliciguat during an additional 24-week open-label extension period. Study results have not yet been presented and will be provided in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620380-en) on January 06, 2026, and is solely responsible for the information contained therein.